BIIB FY 2018 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

FY 2018 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$13.5B+9.6% YoY

Gross Profit

$11.6B86.5% margin

Operating Income

$5.9B43.8% margin

Net Income

$4.4B32.9% margin

EPS (Diluted)

$21.58

Cash Flow

Operating Cash Flow

$6.2B

Free Cash Flow

$5.3B

Stock-Based Comp.

$158M

Balance Sheet

Total Assets

$25.3B

Total Liabilities

$12.3B

Stockholders' Equity

$13.0B

Cash & Equivalents

$1.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13.5B	$12.3B	+9.6%
Gross Profit	$11.6B	$10.6B	+9.3%
Operating Income	$5.9B	$5.3B	+10.2%
Net Income	$4.4B	$2.5B	+74.5%